<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292483</url>
  </required_header>
  <id_info>
    <org_study_id>1900-5, 00-034</org_study_id>
    <nct_id>NCT04292483</nct_id>
  </id_info>
  <brief_title>Pulmonary Capillary Recruitment in Fontan Patients</brief_title>
  <official_title>Pulmonary Capillary Recruitment With Pulmonary Vasodilator Therapy in Patients With Univentricular Heart Physiology and Failing Total Cavo-pulmonary Connection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel Aviv University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Old Dominion University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effects of pulmonary vasodilator therapy on pulmonary capillary
      blood flow by measuring the functional capillary surface area (FCSA) at baseline and post
      nitric oxide inhalation, through the injection of 3H-benzoyl-Phe-Ala-Pro (BPAP). FCSA will be
      related to flow and other hemodynamic parameters in order to determine if there is capillary
      recruitment or distention in Fontan patients. We will also compare baseline FCSA measurements
      with previously studied normal subjects, to assess the difference in hemodynamic pulmonary
      functional parameters between these single ventricle physiology patients and normal subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Functional capillary surface area</measure>
    <time_frame>30 minutes</time_frame>
    <description>Measurement of functional capillary surface area pre and post inhaled nitric oxide</description>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Congenital Heart Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>Inhaled nitric oxide to increase pulmonary capillary perfusion</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Fontan failure as described above
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Fontan failures will be defined as patients with single ventricle physiology and TCPC with
        clinical signs of dysfunction defined as any of the following:

          1. Decreased functional class WHO/NYHA II or more and clinical signs of congestion
             (ascites, peripheral edema, increased JVP) and/or NT-proBNP &gt; 399 pg/ml based on [17].

          2. Age &gt; 18 years

          3. Known Fontan's increased pressures a. Fontan mean pressure of ≥15 mmHg and/or
             transpulmonary gradient ≥ 5 mmHg. b. Pulmonary vascular resistance ≥ 2 woods units.
             And/or supporting evidence of end-organ damage

        1. Clinical or paraclinical evidence of liver congestion and/or fibrosis

        a. Evidence in ultrasound or other imaging techniques of liver congestion and/or changes
        related to cardiac cirrhosis.

        b. Fibroscan with grade 2 or + 2. Paraclinical signs of portal hypertension defined as 2 or
        more:

          1. Thrombocytopenia defined as platelet count &lt; 150.0000

          2. Leukocytopenia defined as white blood cell less than 4.500

          3. Esophageal varices on esophagoduodenoscopy.

          4. Splenomegaly on imaging -

        Exclusion Criteria:

          1. Presence of fenestration - the shunts include veno-veno collaterals

          2. Significant anemia defined as Hgb &lt; 120 mg/dl

          3. Pregnancy at the moment of the procedure.

          4. Taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

          5. Usage of nitrates, phosphodiesterase inhibitors or calcium blockers within 3 months of
             the study.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Langleben, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Langleben, MD</last_name>
    <phone>5143407531</phone>
    <email>david.langleben@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judith Therrien, MD</last_name>
    <phone>514-340-8232</phone>
    <email>judith.therrien@mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>February 29, 2020</last_update_submitted>
  <last_update_submitted_qc>February 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Dr David Langleben</investigator_full_name>
    <investigator_title>Professor of Medicine (Cardiology)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

